# US 2024/0199742 A1 · Methods for treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199742 A1
- Document ID: US20240199742A1
- Status: Published application
- Kind: A1
- Application number: 18/513,146
- Filed: 2023-11-17
- Published: 2024-06-20
- Earliest claimed: 2019-05-10
- Assignees: BicycleRD Limited
- Applicants: BicycleRD Limited
- Inventors: Gavin Bennett; Gillian Langford; Peter Park; Johanna Lahdenranta
- Web page: https://patentgrep.com/patent/US20240199742A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07K 16/2818: {against CD28 or CD152}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 39/39541: {against normal tissues, cells}
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 35/00: Antineoplastic agents
- A61K 2039/505: {comprising antibodies}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a method of treating a cancer in a patient.

## Claims

### Claim 1

A method of treating a cancer in a patient, comprising administering to said patient a therapeutically effective amount of BT1718, or a pharmaceutically acceptable salt thereof, and a checkpoint inhibitor, wherein the cancer is a colon cancer, and wherein the checkpoint inhibitor is a CTLA-4 antagonist.

### Claim at position 2

2-14. (canceled)

### Claim 15 (depends on 1)

The method of claim 1, wherein the method comprises administering BT1718, or a pharmaceutically acceptable salt thereof, at a dose of about 19.2 mg/m2.

### Claim 16 (depends on 1)

The method of claim 1, wherein the method comprises administering BT1718, or a pharmaceutically acceptable salt thereof, at a frequency of once a week.

### Claim 17 (depends on 1)

The method of claim 1, wherein the CTLA-4 antagonist is an anti-CTLA4 antibody.

### Claim 18 (depends on 1)

The method of claim 1, wherein BT1718, or a pharmaceutically acceptable salt thereof, is administered by an intravenous infusion.

### Claim at position 7

19-22. (canceled)

### Claim 23 (depends on 1)

The method of claim 1, wherein the method comprises administering BT1718, or a pharmaceutically acceptable salt thereof, at a dose of about 14.4 mg/m2.

### Claim 24 (depends on 1)

The method of claim 1, wherein the method comprises administering BT1718, or a pharmaceutically acceptable salt thereof, at a dose of about 18.6 mg/m2.

### Claim 25 (depends on 1)

The method of claim 1, wherein the method comprises administering BT1718, or a pharmaceutically acceptable salt thereof, at a dose of about 14-24 mg/m2.

### Claim 26 (depends on 1)

The method of claim 1, wherein the method comprises administering BT1718, or a pharmaceutically acceptable salt thereof, at a dose of about 9-18 mg/m2.

### Claim 27 (depends on 1)

The method of claim 1, wherein the method comprises administering BT1718, or a pharmaceutically acceptable salt thereof, at a frequency of once every 1.5 weeks.

### Claim 28 (depends on 1)

The method of claim 1, wherein the method comprises administering BT1718, or a pharmaceutically acceptable salt thereof, at a frequency of once every 2 weeks.

### Claim 29 (depends on 1)

The method of claim 1, wherein the method comprises administering BT1718, or a pharmaceutically acceptable salt thereof, at a frequency of once every 2.5 weeks.

### Claim 30 (depends on 1)

The method of claim 1, wherein the method comprises administering BT1718, or a pharmaceutically acceptable salt thereof, at a frequency of once every 3 weeks.

### Claim 31 (depends on 1)

The method of claim 1, wherein the method comprises administering BT1718, or a pharmaceutically acceptable salt thereof, at a frequency of once every 4 weeks.

### Claim 32 (depends on 17)

The method of claim 17, wherein the anti-CTLA4 antibody is ipilimumab.

### Claim 33 (depends on 17)

The method of claim 17, wherein the anti-CTLA4 antibody is tremelimumab.

### Claim 34 (depends on 1)

The method of claim 1, wherein BT1718, or a pharmaceutically acceptable salt thereof, is administered with histidine.

### Claim 35 (depends on 1)

The method of claim 1, wherein BT1718, or a pharmaceutically acceptable salt thereof, is administered with sucrose.

### Claim 36 (depends on 1)

The method of claim 1, wherein BT1718, or a pharmaceutically acceptable salt thereof, is administered by an about 1 hour intravenous infusion.

### Claim 37 (depends on 1)

The method of claim 1, wherein BT1718, or a pharmaceutically acceptable salt thereof, is administered with the CTLA-4 antagonist simultaneously or sequentially in separate unit dosage forms.
